Eli Lilly CEO Highlights Growing Market Share for Foundayo Oral GLP-1 Medication
On September 21, Eli Lilly CEO Dave Ricks announced that one-third of new patients starting oral GLP-1 therapy are now choosing the company’s pill, Foundayo. This shift is attributed to Medicare coverage beginning in July and Foundayo's user-friendly dosing—no fasting or injection required—which addresses barriers faced by many potential users. Foundayo achieved significant weight loss results in clinical trials: 7.4% to 11.1% average reduction over 72 weeks, with more than half of patients on the highest dose losing at least 10%. The drug is also gaining traction due to its convenience compared to injectable alternatives like Novo Nordisk’s Wegovy. Lilly is investing heavily in manufacturing capacity for Foundayo and other small-molecule drugs. A $6.5 billion facility under construction near Houston, Texas, will be operational by 2030 as part of a broader $27 billion U.S.-focused expansion plan.
Topics: Eli Lilly GLP-1 medications obesity treatment market oral drug delivery